Syros Pharmaceuticals (NASDAQ: SYRS) reported Q3 EPS of ($3.21), $0.67 better than the analyst estimate of ($3.88). Revenue for the quarter came in at $3.9 million versus the consensus estimate of $5.18 million.

For earnings history and earnings-related data on Syros Pharmaceuticals (SYRS) click here.